TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11105736
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of prior antipsychotic drug
Study: 11105736
Drug: Gradual discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual discontinuation of prior antipsychotic drug
Study: 16899362
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg daily for the first 7 days, increased by 25 mg each week up to 150 mg
Study: 16899362
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg daily for 21 days followed by a 7-day rest period, repeated for 3 cycles
Study: 3927958
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg thrice daily
Study: 3510823
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg thrice daily
Study: 29486097
Drug: STH+G advertisements
Approvals — FDA: no, EMA: no, PMDA: no
Description: STH+G advertisements
Study: 19965693
Drug: Normal D-dimer
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal D-dimer (D-d) at 1 month after anticoagulation suspension
Study: 12843147
Drug: AC2993 (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC2993 (synthetic exendin-4; exenatide) 0.1 micro g/kg, administered sc twice daily with meals for 5 days
Study: 10190914
Drug: Azlocillin and
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azlocillin and tobramycin (combination therapy)
Study: 18191322
Drug: Immediate androgen-deprivation
Normalized name: hydrogen peroxide Topical Solution [IR DIP 10]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate androgen-deprivation therapy (ADT)
Study: 18191322
Drug: Deferred androgen-deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred androgen-deprivation therapy (ADT)
Study: 16843101
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate treatment for more than 1.5 years
Study: 12771601
Drug: Gatifloxacin intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin intravenous administration
Study: 25923045
Drug: Metoclopramide (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.2 mg/kg)
Study: 3017797
Drug: Propranolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta 1 + beta 2‐antagonist)
Study: 12556096
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate depot (3.75 mg every 28 days for 24 weeks)
Study: 2390157
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose (25g)
Study: 7011331
Drug: Org GC
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org GC 94 (3 x 5 mg/day for 3 months)
Study: 7011331
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 x 0.5 mg or placebo daily)
Study: 20976217
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPTp‐SP)
Study: 16117182
Drug: L-lysine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine and L-arginine (3 g each/day) for 10 days
Study: 9773701
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone 2 microg/kg/h
Study: 9773701
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline infusion only
Study: 7812025
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with 5‐ASA tablets (2.4 g for the first week of each month)
Study: 7812025
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 5‐ASA tablets (1.6 g each day)
Study: 3166357
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (12 1-g capsules daily)
Study: 30760751
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of oxytocin (OT)
Study: 8299455
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin injected subcutaneously in the thigh
Study: 31813614
Drug: On-Idebenone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-Idebenone (900 mg/day)
Study: 29953297
Drug: 1 ounce
Normalized name: Ointment Jar, 1 ounce
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ounce of an exogenous BHB solution (KETO)
Study: 28854283
Drug: Transdermal rivastigmine
Normalized name: rivastigmine Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rivastigmine (9.5 mg daily)
Study: 28854283
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no new medication)
Study: 23680517
Drug: Barbed suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbed suture (Quill; Angiotech Pharmaceuticals, Inc.)
Study: 21733822
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg bid for 6 months)
Study: 18696173
Drug: Combination resistance
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination resistance and balance-jumping training (COMB)
Study: 16914029
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and/or long-acting beta-2-agonists
Study: 16914029
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (neither inhaled corticosteroids nor long-acting beta-2-agonists)
Study: 2959924
Drug: Aminophylline (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (oral, sustained-release)
Study: 26370187
Drug: sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400 mg, twice daily)
Study: 21752453
Drug: Seminal doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seminal doses of buserelin acetate (5 μg) with varying sperm counts (6, 12, 24, 50, and 100 million total sperm in 0.5 mL)
Study: 21752453
Drug: Seminal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seminal plasma dilutions (1/4 and 1/20) with 5 μg of buserelin acetate
Study: 21752453
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg of buserelin acetate administered intramuscularly
Study: 22784653
Drug: CO(2) laser
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO(2) laser therapy
Study: 16955427
Drug: Sertraline (treatment)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (treatment)
Study: 16955427
Drug: CSDD mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSDD mood subscale (treatment)
Study: 16955427
Drug: NPI-M (treatment)
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPI-M (treatment)
Study: 8874332
Drug: Paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 125 mg/m2 over 24 hours followed by doxorubicin 48 mg/m2 over 48 hours
Study: 1989806
Drug: Slow Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Intralipid infusion (500 ml, 20 percent, infused over 10 hours)
Study: 1989806
Drug: Both fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both fast and slow Intralipid infusion
Study: 30882162
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of povidone‐iodine solution (0.1 g/mL) into the anal and lower rectal canals (Group II, n=116)
Study: 22932146
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg/kg
Study: 31008751
Drug: Dexmedetomidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.75 µg/kg
Study: 22339553
Drug: Topical product
Normalized name: Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical product for night-time application aimed at adipolysis and microcirculation stimulation
Study: 20596066
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment based on traditional Chinese medicine
Study: 12368570
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olmesartan medoxomil q.d.
Study: 12368570
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg olmesartan medoxomil q.d.
Study: 12368570
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg olmesartan medoxomil q.d.
Study: 12368570
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg olmesartan medoxomil b.i.d.
Study: 10202830
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 65 mg weekly
Study: 10202830
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 200 mg fortnightly (open-label)
Study: 335419
Drug: Piracetam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (3 tablets or 1.2 g for second and third graders; 5 tablets or 2.0 g for fourth graders)
Study: 30535534
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum, 2 × 10^9 CFU/g each) for 6 weeks
Study: 20545209
Drug: Fupiyiwei decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fupiyiwei decoction (FPYWD) combined with chemotherapy
Study: 29562855
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotherapy only)
Study: 12841885
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg/day) continuously
Study: 11299497
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g i.v. amoxicillin/clavulanic acid (Group 1)
Study: 11299497
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics commonly used for prophylaxis (Group 2)
Study: 1996000
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of epinephrine (1 mg)
Study: 1996000
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of epinephrine (0.2 mg/kg)
Study: 6350014
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (0.01 X 10(6) IU)
Study: 30690609
Drug: TheraBracelet stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TheraBracelet stimulation during task-practice therapy
Study: 11981142
Drug: Dextromethorphan (dose-response)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (dose-response)
Study: 10772554
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg (two doses)
Study: 17805102
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg.d(‐1) for 1 wk)
Study: 6107725
Drug: Water-deprived volunteers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-deprived volunteers (after DAMME administration)
Study: 22649162
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy
Study: 27714763
Drug: Amiselimod (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiselimod (1 mg·kg‐1)
Study: 27714763
Drug: Fingolimod (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (1 mg·kg‐1)
Study: 25881262
Drug: Daily provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily provision of free fruit and vegetables (FV)
Study: 25881262
Drug: Daily offering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily offering of FV by teachers
Study: 23666608
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 or 100 mg every 4 weeks
Study: 22072405
Drug: Telemedicine Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine Cognitive Behavioral Therapy (TV‐CBT)
Study: 22072405
Drug: Face-to-Face Cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-Face Cognitive Behavioral Therapy (FTF‐CBT)
Study: 17471295
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and pharmacological treatment
Study: 2568520
Drug: Calcium-heparin, 12,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-heparin, 12,500 U, subcutaneously
Study: 28556806
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle (PFM) exercises without TrA tension for 3 months, 4 weekly sessions
Study: 24977700
Drug: Caffeine (6.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6.04 +/- 0.16 mg/kg)
Study: 21240873
Drug: Everolimus +
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus + CsA + steroids
Study: 21240873
Drug: EC‐MPS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS + CsA + steroids
Study: 15217964
Drug: Gefitinib (Iressa)
Normalized name: gefitinib Oral Tablet [Iressa]
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib (Iressa) as second-line therapy
Study: 15217964
Drug: Gefitinib in
Normalized name: Product containing gefitinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib in combination with chemotherapy (first-line therapy)
Study: 11503006
Drug: Ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 75 mg
Study: 10215729
Drug: Ranitidine 25
Normalized name: ranitidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 25 mg
Study: 11704778
Drug: Ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 75 mg and 25 mg
Study: 27900849
Drug: Standard approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard approach (low-energy diet and physical activity prescription)
Study: 27270279
Drug: High dosing
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h)
Study: 27270279
Drug: Extended-interval high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-interval high loading dose of amikacin (25 mg/kg every 48 h) with therapeutic drug monitoring (TDM)
Study: 24349782
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 4.0 mg supplementation throughout pregnancy
Study: 16498855
Drug: Fexofenadine hydrochloride,
Normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride, 180 mg
Study: 2887328
Drug: Cetirizine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10 mg
Study: 8997048
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg.kg‐1
Study: 1336008
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) administration as monochemiotherapy
Study: 1336008
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) administration in combination with glutathione
Study: 29369914
Drug: ANT1 soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT1 soybean extract cream
Study: 24942055
Drug: Morphine (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.25, 0.75 or 1.25 mg/100 cm² wound size) in hydroxyethylcellulose gel
Study: 22275444
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of metformin
Study: 16899628
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg daily
Study: 25213088
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical therapy
Study: 8791952
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m. plus clarithromycin 250 mg b.d. and amoxycillin 1000 mg b.d. (group B)
Study: 1298088
Drug: Quinine, quinidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine, quinidine, and cinchonine combination (600 mg regimen)
Study: 1298088
Drug: Quinine, quinidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine, quinidine, and cinchonine combination (400 mg regimen)
Study: 1298088
Drug: Quinine, quinidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine, quinidine, and cinchonine combination
Study: 6098221
Drug: Systemic acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic acyclovir (ACV) therapy
Study: 26398126
Drug: Low injection
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low injection speed (60 seconds)
Study: 26398126
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection speed (100 seconds)
Study: 7899001
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Tiapride
Study: 7899001
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Tiapride
Study: 7899001
Drug: Follow-up observation
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up observation without medication
Study: 25393414
Drug: Psychodynamic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic group art therapy plus treatment as usual
Study: 18831691
Drug: High-dose folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folate supplementation (5 mg daily)
Study: 18831691
Drug: Low-/moderate-dose folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-/moderate-dose folate supplementation
Study: 12923794
Drug: Cognitive-existential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-existential group therapy (CEGT)
Study: 8262577
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose diazepam (67 +/- 9.3 mg)
Study: 8262577
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose diazepam (200 mg)
Study: 3516189
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg i.m. 120 min before induction
Study: 26181573
Drug: Yoga practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga practice (90 minutes once a week for 12 weeks, plus daily home practice for 40 minutes)
Study: 20811340
Drug: Donepezil (cholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (cholinesterase inhibitor)
Study: 10741710
Drug: GM2-KLH/QS21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM2-KLH/QS21 vaccine at GM2 doses of 1, 3, 10, 30, or 70 microg
Study: 10741710
Drug: GM2-KLH/QS21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM2-KLH/QS21 vaccine at 30 microg dose
Study: 10741710
Drug: GM2-KLH/QS21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM2-KLH/QS21 vaccine (doses of 3-70 microg)
Study: 10741710
Drug: Previous vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous vaccine formulation (GM2 and bacille Calmette-Guerin)
Study: 1627202
Drug: Sertaconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 1% cream, twice a day for 28 days
Study: 6729761
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg + placebo
Study: 2628134
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (5 mg)
Study: 25099540
Drug: HOS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HOS + fish oil (FO; 5 g EPA and DHA)
Study: 25099540
Drug: HOS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HOS + algal oil (AO; 5 g DHA)
Study: 23950178
Drug: Panobinostat in
Normalized name: Product containing panobinostat in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat in combination with bortezomib and dexamethasone
Study: 27001985
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with bortezomib and dexamethasone
Study: 10872756
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose control group
Study: 10872756
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose group
Study: 1899636
Drug: Oral streptokinase-streptodornase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral streptokinase-streptodornase (SS), dosage: two tablets three times a day for eight days
Study: 12472909
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg day-1